Aimei Health Technology Co., Ltd. AFJK
Last close
12.20
2026-09-04
Market cap
$38.6M
2026-06-30 share count
52-week range
6.75 - 130.37
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating income | -$835.8K | -$1.1M | — |
| Pre-tax income | $1.1M | $2.6M | — |
| Income tax | $0 | $0 | $0 |
| Net income | $1.1M | $2.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total current assets | $2.9K | $30.4K | $580.7K |
| Total assets | $12.1M | $73.8M | $70.5M |
| Total current liabilities | $3.4M | $817.0K | $24.8K |
| Total liabilities | $4.1M | $1.5M | $714.8K |
| Retained earnings | -$4.1M | -$1.5M | -$134.3K |
| Total equity | -$4.1M | -$1.5M | -$134.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$565.1K | -$672.3K | — |
| Investing cash flow | $63.6M | -$277.7K | — |
| Financing cash flow | -$63.0M | $397.5K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-021108.
Others in SIC 6770
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DMII | Drugs Made In America Acquisition II Corp. | $647.8M | — | — |
| IACO | Idea Acquisition Corp. | $437.1M | — | — |
| KRAQ | KRAKacquisition Corp | $431.6M | — | — |
| TACO | Berto Acquisition Corp. | $393.6M | 36.2x | — |
| ALDF | Aldel Financial II Inc. | $322.7M | — | — |
| ATII | Archimedes Tech SPAC Partners II Co. | $315.1M | — | — |
| FGII | FG Imperii Acquisition Corp. | $289.7M | — | — |
| SOUL | Soulpower Acquisition Corp. | $268.0M | — | — |